Unlocking the Potential of RPL28: A novel 60S Ribosomal Protein L28 (ISO Form 3) as a Drug Target and Biomarker

Target Name: RPL28

NCBI ID: G6158

RPL28

Unlocking the Potential of RPL28: A novel 60S Ribosomal Protein L28 (ISO Form 3) as a Drug Target and Biomarker

Abstract:

RPL28, a 60S ribosomal protein L28 (ISO Form 3), is a key regulator of rRNA synthesis in eukaryotic cells. The aim of this article is to investigate the potential of RPL28 as a drug target and biomarker. We review the current literature on RPL28 and its functions, as well as the current research on its potential as a drug target. We discuss the potential benefits and challenges of targeting RPL28 and suggest directions for future research.

Introduction:

Ribosomes are complex organelles responsible for the synthesis of proteins in eukaryotic cells. The 60S ribosomal protein L28 (ISO Form 3) is a key regulator of rRNA synthesis in these cells. It plays a critical role in the assembly, stability, and quality of rRNAs , and is expressed in high levels in various cellular organelles and cell types [1,2].

Recent studies have identified RPL28 as a potential drug target and biomarker. Its functions in regulating rRNA synthesis have led to the exploration of new therapeutic approaches for various diseases, including cancer, neurodegenerative diseases, and Inflammatory diseases [3,4].

Current Literature on RPL28:

RPL28 is a 60S ribosomal protein L28 (ISO Form 3) that contains 21kDa of protein and 4kDa of a hypervariable region (HVR) [5,6]. It is a key regulator of rRNA synthesis, and its functions in this process include:

1. Controlling rRNA biosynthesis: RPL28 plays a critical role in regulating the biosynthesis of rRNAs by affecting the activity of the ribosome. It does this by interacting with the ribosome's S1 subunit and by modulating the composition of the rRNA pool [7,8].

2. Regulating rRNA stability: RPL28 is involved in the stability of rRNAs by affecting their interactions with various cellular factors, including the microtubules of the mitotic spindle [9,10].

3. Controlling rRNA quality: RPL28 is responsible for the quality control of rRNAs by regulating the addition of various post-translational modifications, such as polyA tail and window[11,12].

Potential Therapeutic Applications of RPL28:

The potential therapeutic applications of RPL28 are vast and span across various diseases. Its functions in regulating rRNA synthesis make it an attractive target for the development of new treatments:

1. Cancer: RPL28 has been shown to be involved in the regulation of rRNA synthesis in various cancer types, including breast, ovarian, and colorectal cancers [13,14]. Therefore, targeting RPL28 may be a promising strategy for the development of new cancer therapies.

2. Neurodegenerative Diseases: RPL28 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease [15,16]. Therefore, targeting RPL28 may be a promising strategy for the development of new neurodegenerative therapies.

3. Inflammatory Diseases: RPL28 has been shown to be involved in the regulation of rRNA synthesis in various inflammatory diseases, including rheumatoid arthritis, asthma, and inflammatory bowel disease [17,18]. Therefore, targeting RPL28 may be a promising strategy for the development of new inflammatory therapies.

Current Challenges and Future Directions:

Targeting RPL28

Protein Name: Ribosomal Protein L28

Functions: Component of the large ribosomal subunit (PubMed:12962325, PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:12962325, PubMed:23636399, PubMed:32669547)

The "RPL28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets